This publication supports the scientific groundwork for the CREAATE study but provides no new clinical data or regulatory milestone. The near-term catalyst remains the Phase 3 CREAATE readout and the HAE NDA outcome. Monitor for those events, this filing alone does not change the stock's trajectory.
Drug in focus
PHVS drug pipeline →deucrictibant
◆ Mixed Named in this press release- Impact
- Phase
- Filed/PDUFA (IR capsule); Phase 3 (XR tablet)
- Time to market
- IR capsule could be approved by April 23, 2027 PDUFA date. XR tablet for prophylaxis would follow later, likely 2028+ if CHAPTER-3 is positive.
- Next catalyst
- None dated
What to watchTwo binary catalysts in the next ~9 months: CHAPTER-3 topline (Q3 2026) and the PDUFA decision on the IR capsule (April 23, 2027). The bigger swing factor near-term is CHAPTER-3, a positive readout would validate the larger prophylactic market opportunity, while a miss would severely dent the thesis given that sebetralstat (KalVista) already beat deucrictibant to market as the first oral on-demand HAE therapy.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 6 $34.45entry
- T+1 · 3mo ago +1.34%α +0.72% · $34.91
- T+5 · 3mo ago −1.19%α −2.40% · $34.04
- T+20 · 3mo ago +3.51%α +2.91% · $35.66
- T+60 · 18d ago −2.53%α −1.10% · $33.58
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Pharvaris announced publication of the first in-depth qualitative study in AAE-C1INH in Frontiers in Immunology, validating PRO measures and directly informing endpoint selection for the ongoing Phase 3 CREAATE study of deucrictibant. There are currently no approved therapies for this ultra-rare, serious disease. This is a scientific milestone that supports the regulatory path but does not change the stock's near-term fundamentals.
Key Facts
- First in-depth qualitative study in AAE-C1INH published in peer-reviewed journal Frontiers in Immunology.
- Study validates PGI-C, PGI-S, and PGA as meaningful PRO instruments for this indication.
- Findings directly informed design and endpoint selection for the ongoing Phase 3 CREAATE study (NCT07266805) of deucrictibant.
- No approved therapies exist for prevention or treatment of AAE-C1INH attacks, all patients currently rely on off-label therapies.
- Pharvaris is a late-stage biopharma developing oral bradykinin B2 receptor antagonists for bradykinin-mediated angioedema.
Financial Impact
No financial data disclosed; the announcement pertains to a disease framework publication, not financial results or deal terms.
Risk Factors
- CREAATE study may fail to replicate prior deucrictibant efficacy/safety in AAE-C1INH.
- Regulatory path for AAE-C1INH remains unclear; FDA may require additional trials beyond CREAATE.
- Deucrictibant NDA for HAE on-demand treatment has uncertain outcome and timeline.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3340059 |
Track record
51 reports on PHVS
15 of 18 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 17 of 19 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
- Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Nov 12, 20264d ago 6-K Neutral 4/10 No price data
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
- Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers